Healthcare |
Update
Healthcare |
Update
Healthcare |
Flash note
Healthcare |
Update
% | 1M | 3M | 12M |
---|---|---|---|
Actual | 14.5 | 4.2 | 12.9 |
Relative | 14.1 | 7.6 | 9.3 |
52 week high/low | 1380.0p/910.0p |
Ergomed reported FY22 results broadly in line with our expectations. Group revenues grew 22.5% y-o-y to £145.3m, underpinned by sustained demand for both the CRO and PV segments and supported by the ADAMAS acquisition and foreign exchange benefit. Adjusted EBITDA rose 11.5% y-o-y, although margins were comparatively lower (19.5% versus 21.4% in FY21) due to previously flagged incremental investments in technology and senior management hires. The order book remained robust at £295m (up 23.1% over FY21), boding well for medium-term sales potential. Year-end net cash of £19.1m was an improvement over the £12m reported in H122 (after the £24.2m net cash purchase of ADAMAS in February 2022) and, with £80m in undrawn credit facilities, Ergomed remains well-capitalised to fund future growth. We make minor adjustments to our estimates and roll forward our model. We upgrade our valuation slightly to 1,577p/share from 1,573p/share previously.
Y/E Dec | Revenue (£m) | EBITDA (£m) | PBT (£m) | EPS (fd) (p) | P/E (x) | P/CF (x) |
---|---|---|---|---|---|---|
2021A | 118.6 | 25.4 | 21.6 | 39.6 | 26.3 | 27.0 |
2022A | 145.3 | 28.4 | 24.3 | 41.6 | 25.0 | 34.9 |
2023E | 158.3 | 31.3 | 27.9 | 44.5 | 23.4 | 21.3 |
2024E | 176.3 | 35.3 | 31.9 | 51.2 | 20.4 | 18.5 |
thematic
Financials
thematic
Healthcare
thematic
Industrials
thematic
Financials
thematic
Energy & Resources
thematic
Healthcare
thematic
Healthcare
thematic
Metals & Mining
thematic
Energy & Resources
thematic
Energy & Resources
thematic
Energy & Resources
thematic
Energy & Resources
thematic
Energy & Resources
thematic
Energy & Resources
thematic
Energy & Resources
thematic
Energy & Resources
thematic
Energy & Resources